Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Zakattack who wrote (7740)	4/16/1998 2:55:00 PM
From: Money Maker (MM)	Read Replies (1) \| Respond to of 34592

So, if NTST close above $1, will it still be Copia's pick for tomorrow?

To: Zakattack who wrote (7740)	4/16/1998 2:58:00 PM
From: makin_dough99	Read Replies (1) \| Respond to of 34592

Thanks for the info - you are indeed a gentleman ! How many are you buying? Should I buy it also.

To: Zakattack who wrote (7740)	4/16/1998 3:02:00 PM
From: barbara sperino	Respond to of 34592

You might be right , but I think I will wait to hear it from the horses mouth, so to speak.

To: Zakattack who wrote (7740)	4/16/1998 3:36:00 PM
From: Dave Gore	Read Replies (1) \| Respond to of 34592

STRONGLY RECOMMEND <LCAV> look at this news....hot industry "PaineWebber estimated that 70,000 people were treated in the United States in 1996, rising to 200,000 in 1997, with further growth to an estimated 350,000 this year, and to 500,000 to 550,000 in 1999." "There is a potential laser-treatment market of 60 million near-sighted people and 50 million far-sighted people in the United States, Koo said." "It's a lifestyle change," he added. "The outlook is going to be quite positive as vision-correction (surgery) continues to gain acceptance." Laser Vision's stock was up 15/16 at 11-5/16. LCA's stock <LCAV> was up 5/16 at 2-5/8. NEW YORK, April 16 (Reuters) - Laser eye treatment stocks rallied on Thursday after better-than-expected profits at VISX Inc. injected further credibility into a sunrise industry as public confidence in the procedure grows. "VISX's earnings validate the growth in the procedure that we have been talking about," said Charles Olsziewski, a first vice president at PaineWebber. VISX's net income in the first quarter of this year rose to a record $0.58 per share, up from $0.17 per share in the same quarter last year. The treatment of near- and far-sightedness using lasers began about three years ago.